Cutaneous Adverse-Event Reporting Patterns of Bruton Tyrosine Kinase Inhibitors: A Multi-Database Pharmacovigilance Analysis
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background: Bruton tyrosine kinase inhibitors (BTKi) are widely used for B-cell malignancies and chronic graft-versus-host disease, but their real-world dermatologic reporting profile remains incompletely defined. Methods: We performed a multi-database pharmacovigilance analysis of BTKi primary suspect reports in FAERS, Canada Vigilance, and JADER. Outcomes included any-cutaneous adverse event, a prespecified 14-category morphology panel, severe cutaneous reaction controls, cutaneous malignancy, latency, and exploratory wound/ulcer and neutrophilic-dermatosis phenotypes. Reporting odds ratios (RORs), Evans criteria, a mutually exclusive haematologic-oncology disease-context comparator, multivariable models, and cross-database replication were used. Results: FAERS contained 75,681 BTKi primary suspect reports among 12,838,382 reports; Canada Vigilance contained 4649 among 1,234,555; and JADER contained 1822 BTKi suspect reports among 1,027,194. Vascular-cutaneous events showed the most prominent class-level reporting pattern (FAERS ROR 7.97, 95% CI 7.43–8.56; disease-context ROR 6.38, 95% CI 5.84–6.97), with similar disproportionate reporting observed in Canada Vigilance and JADER. Of 802 vascular-cutaneous reports, 777 (96.9%) described bleeding manifestations without vasculitis, whereas 22 (2.7%) included vasculitis as a reported event; cutaneous vasculitis itself was not disproportionately reported (19 reports; ROR 1.38, 95% CI 0.89–2.16). Wound/ulcer events met the Evans criteria for disproportionate reporting in FAERS and were directionally elevated against the full Canada Vigilance background, but not against the Canadian disease-context comparator. Exploratory analyses showed disproportionate reporting for the neutrophilic-core phenotype (disease-context ROR 1.99, 95% CI 1.50–2.66) and pyoderma gangrenosum (ROR 2.87, 95% CI 1.98–4.16). Non-melanoma skin cancer remained disproportionately reported after disease-context adjustment in FAERS (adjusted OR 1.54, 95% CI 1.39–1.71), and was reproduced in Canada Vigilance. A shorter latency period was identified for bleeding than for cutaneous malignancy (median, 1.1 vs. 9.3 months). In SJS/TEN culprit-drug co-exposure analyses, concomitant BTK inhibitor exposure did not show greater disproportionate SJS/TEN reporting than the corresponding culprit-drug-only groups. Conclusions: BTKi-associated dermatologic reports identified three main patterns: early cutaneous bleeding, wound-and-ulcer events with an exploratory neutrophilic-dermatosis component, and later cutaneous malignancy. These findings support the early assessment of bleeding and non-healing ulcers and longer-term skin surveillance during BTKi treatment. Spontaneous-reporting data cannot determine incidence, confirm causality, establish comparative product safety, or accurately adjudicate clinical diagnoses and event timing.
Source: Cancers
Institutions: Nottingham University Hospitals NHS Trust, University of Nottingham, Nottingham Biomedical Research Centre, University of Hull, Hull York Medical School, Yale New Haven Hospital, Yale Cancer Center, Smilow Cancer Hospital, Queen's University Belfast, Sheffield Teaching Hospitals NHS Foundation Trust, Imperial College London
Language: English
Subfield: Toxicology
Domain: Life Sciences
Keywords: BTK inhibitors, cutaneous adverse events, drug safety, cutaneous vasculitis, pyoderma gangrenosum, neutrophilic dermatosis, skin cancer, bleeding manifestations, B-cell malignancies, graft-versus-host disease, FDA Adverse Event Reporting System, JADER, disproportionality analysis, reporting odds ratio
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W7234432227
